Search Results - "Petracci, E"

Neuropathy in multiple myeloma treated with thalidomide : A prospective study by PLASMATI, R, PASTORELLI, F, MICHELUCCI, R, TASSINARI, C. A, CAVO, M, PETRACCI, E, ZAMAGNI, E, TOSI, P, CANGINI, D, TACCHETTI, P, SALVI, F, BARTOLOMEI, I

“…Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity. To study the…”
Get full text

Risk Factor Modification and Projections of Absolute Breast Cancer Risk by Petracci, Elisabetta, Decarli, Adriano, Schairer, Catherine, Pfeiffer, Ruth M., Pee, David, Masala, Giovanna, Palli, Domenico, Gail, Mitchell H.

“…Background Although modifiable risk factors have been included in previous models that estimate or project breast cancer risk, there remains a need to estimate…”
Get full text

Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates by González-Hurtado, Daniel, Rivero, Sergio, Samamé Pérez-Vargas, Juan Carlos, Petracci, Fernando E.

“…Prognostic and predictive factors for early and late distant distance recurrence risk in estrogen-receptor positive and HER2-receptor negative early breast…”
Get full text

Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial by Grassi, E., Zingaretti, C., Petracci, E., Corbelli, J., Papiani, G., Banchelli, I., Valli, I., Frassineti, G.L., Passardi, A., Di Bartolomeo, M., Pietrantonio, F., Gelsomino, F., Carandina, I., Banzi, M., Martella, L., Bonetti, A.V., Boccaccino, A., Molinari, C., Marisi, G., Ugolini, G., Nanni, O., Tamberi, S.

“…This study investigated the efficacy of chemoradiotherapy (CRT) followed by durvalumab as neoadjuvant therapy of locally advanced rectal cancer. The PANDORA…”
Get full text

Prediction bands and intervals for the scapulo-humeral coordination based on the Bootstrap and two Gaussian methods by Cutti, A.G, Parel, I, Raggi, M, Petracci, E, Pellegrini, A, Accardo, A.P, Sacchetti, R, Porcellini, G

“…Abstract Quantitative motion analysis protocols have been developed to assess the coordination between scapula and humerus. However, the application of these…”
Get full text

Gastric GISTs: Analysis of c-Kit , PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients – A GIRCG study by Capelli, L, Petracci, E, Quagliuolo, V, Saragoni, L, Colombo, P, Morgagni, P, Calistri, D, Tomezzoli, A, Di Cosmo, M, Roviello, F, Vindigni, C, Coniglio, A, Villanacci, V, Catarci, M, Coppola, L, Alfieri, S, Ricci, R, Capella, C, Rausei, S, Gulino, D, Amadori, D, Ulivi, P

“…Abstract Background Gastric gastrointestinal stromal tumors (GISTs) represent a subgroup of GISTs with a better prognosis than those located in other areas. In…”
Get full text

Bootstrap prediction bands of scapula kinematics based on the iseo protocol by Parel, I, Cutti, A.G, Raggi, M, Petracci, E, Pellegrini, A, Porcellini, G, Verni, G

Get full text

Variance computations for functional of absolute risk estimates by Pfeiffer, R M, Petracci, E

“…We present a simple influence function based approach to compute the variances of estimates of absolute risk and functions of absolute risk. We apply this…”
Get full text

Variance computations for functionals of absolute risk estimates by Pfeiffer, R.M., Petracci, E.

“…We present a simple influence function based approach for computing the variances of estimates of absolute risk and functions of absolute risk. We apply this…”
Get full text

Adherence to antihypertensive drug treatment and blood pressure control: a real practice analysis in Italy by Di Martino, M, Veronesi, C, Degli Esposti, L, Scarpa, F, Buda, S, Didoni, G, Petracci, E, Valpiani, G, Degli Esposti, E

Get full text

The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review by Narvaez, Dana, Nadal, Jorge, Nervo, Adrian, Costanzo, María Victoria, Paletta, Claudio, Petracci, Fernando E, Rivero, Sergio, Ostinelli, Alexis, Freile, Berenice, Enrico, Diego, Pombo, Maria Teresa, Amat, Mora, Aguirre, Edgar Danilo, Chacon, Matias, Waisberg, Federico

“…This narrative review aims to clarify the role of tertiary lymphoid structures in breast cancer. We examine their development, composition, and prognostic…”
Get full text

[703] NONALCOHOLIC FATTY LIVER DISEASE INCREASES THE CALCULATED RISK OF CORONARY HEART DISEASE: RESULT FROM A CROSS-SECTIONAL, POPULATION STUDY by Colecchia, A, Vestito, A, Petracci, E, Bacchi-Reggiani, M.L, Di Biase, A.R, Mazzella, G, Pasqui, F, Festi, D

Get full text

Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2 by Narváez, Dana, Waisberg, Federico, Soule, Tomas, Angel, Martín, Bruno, Luisina, Girotti, Maria Romina, Pupareli, Carmen, Chacón, Matías, Petracci, Fernando E

“…BackgroundNext-generation sequencing (NGS) has proven to be a key implementation to understanding biological pathways involved in cancer. In daily practice,…”
Get full text

LuciA-15 - a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and/or somatic mutation of BRCA genes or homologous recombination repair related genes by Petracci, Fernando E, Villarreal-Garza, Cynthia, Argañaraz, Facundo, Abuin, Gonzalo Gómez, Peñaloza, José, Flores, Marcos Ariel, Piazzoni, Luciano, Riggi, Cecilia, Fabiano, Lucía, González, Lucía, Cieplinski, Belén, Rivero, Sergio, Korbenfeld, Ernesto, Mandó, Pablo

“…Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) improve progression free survival among patients with HER2 negative (HER2-ve) advanced breast…”
Get full text

2248P Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results by Tamberi, S., Marisi, G., Molinari, C., Grassi, E., Petracci, E., Angeli, D., Virga, A., Banchelli, I., Zingaretti, C., Pietrantonio, F., Gelsomino, F., Carandina, I., Banzi, M., Bonetti, A., Frassineti, G.L., Ugolini, G., Santucci, S., Longobardi, J., Ulivi, P.

Get full text

590P Assessment of circulating tumor (ct)DNA in patients (pts) with locally advanced rectal cancer (LARC) pts treated with neoadjuvant therapy (NAT) by Molinari, C., Marisi, G., Laliotis, G., Spickard, E., Rapposelli, I.G., Petracci, E., George, G.V., Sharma, S., Jurdi, A., Sethi, H., Liu, M.C., Ulivi, P., Canale, M., Saragoni, L., Panzacchi, R., Frassineti, G.L., Muratore, M., Romeo, A., Martinelli, G., Passardi, A.

Get full text

21P Circulating free and extracellular vesicles-derived microRNA as prognostic biomarkers in resected early-stage non-small cell lung cancer by Ulivi, P., Pasini, L., Petracci, E., Urbini, M., Felip, E., Stella, F., Davoli, F., Salvi, M., Beau-Faller, M., Tebaldi, M., Azzali, I., Solli, P., Lai, G., Amat, R., Carbonell, C., Martinez-Marti, A., Pencreach, E., Delmonte, A., Crinò, L.

Get full text

16P The role of systemic immunity in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy by Molinari, C., Bulgarelli, J., Rebuzzi, F., Camara, R., Dimitropoulou, V. Kokala, Petracci, E., Ewald, J., Prascevic, D., Ulivi, P., Canale, M., Monti, M., Tamberi, S., Derventzi, A.

Get full text

170P Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy by Molinari, C., Marisi, G., Virga, A., Urbini, M., Rebuzzi, F., Limarzi, F., Petracci, E., Prascevic, D., Ewald, J., Canale, M., Ulivi, P., Monti, M., Morgagni, P., Gallo, G.

Get full text

1534P - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment by Canale, M., De Luigi, N., Petracci, E., Delmonte, A., Ludovini, V., Dubini, A., Baglivo, S., Minenza, E., Chiadini, E., Landi, L., Papi, M., Bronte, G., Crinò, L., Ulivi, P.

“…Non-small cell lung cancer (NSCLC) patients carrying epidermal growth factor receptor (EGFR) mutations are sensitive to tyrosine kinase inhibitors (TKIs);…”
Get full text